Jan-Paul Simard, Co-Chief Executive Officer of XBiotech Inc., filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission on October 28, 2026, reflecting a triggering event date of October 23, 2026.

Key Highlights

  • Reporting person: Jan-Paul Simard, identified as Co-Chief Executive Officer of XBiotech Inc.
  • Triggering event date: October 23, 2026, which required the initial beneficial ownership statement.
  • No securities held: The filing states "No securities are beneficially owned" at the time of filing.
  • No derivative securities: Tables I and II both reflect no directly or indirectly held securities or derivative securities prior to the option grant noted in a contemporaneously filed document.
  • Filing date: The statement was signed and filed on October 28, 2026.
  • Issuer: XBiotech Inc., trading on NASDAQ:XBIT.

Simard's Initial Ownership Position at XBiotech as Co-CEO

According to the filing, Jan-Paul Simard submitted this initial statement in connection with his role as Co-Chief Executive Officer at XBiotech Inc. (NASDAQ:XBIT), a clinical-stage biopharmaceutical company. The statement was required under Section 16(a) of the Securities Exchange Act of 1934, which mandates that officers and directors report their beneficial ownership of issuer securities upon assuming a covered role.

The filing discloses that, as of the triggering event date of October 23, 2026, Simard held no securities and no derivative securities of XBiotech, either directly or indirectly. The filing's remarks section states: "No securities or derivative securities were beneficially owned prior to the option grant set forth in the Form 4 being filed contemporaneously herewith," and further confirms "No securities are beneficially owned." Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, were left blank consistent with this disclosure.

XBiotech is engaged in the discovery and development of therapeutic antibodies. Simard's appointment to the Co-Chief Executive Officer position is the event requiring the initial ownership statement, per the filing. A separate document was noted as being filed at the same time, referencing an option grant, though the details of that grant are contained in that concurrent filing rather than in this initial statement.

What Was Disclosed

XBiotech Inc. Co-Chief Executive Officer Jan-Paul Simard filed an initial beneficial ownership statement dated October 23, 2026, disclosing that he held no securities or derivative securities of the company at the time of the triggering event.